Percutaneous Puncture Robot Market Size, Share, Growth, and Industry Analysis, By Type ( Biopsy,Treat ), By Application ( Lung Cancer Detection,Breast Cancer Detection,Prostate Cancer Detection ), Regional Insights and Forecast to 2035

Percutaneous Puncture Robot Market Overview

Global Percutaneous Puncture Robot market size is anticipated to be worth USD 609.5 million in 2026, projected to reach USD 987.06 million by 2035 at a 5.6% CAGR.

The Percutaneous Puncture Robot Market represents a rapidly evolving segment of the medical robotics industry focused on image-guided needle placement systems used in minimally invasive procedures. Percutaneous puncture robots integrate CT, MRI, ultrasound, and fluoroscopy guidance systems with robotic arms that can position needles with accuracy levels often within 1–2 mm deviation. Hospitals performing more than 25 million minimally invasive diagnostic procedures annually worldwide are increasingly adopting robotic assistance to improve procedural success rates above 90% accuracy.

The United States represents one of the most technologically advanced environments for the Percutaneous Puncture Robot Market, with more than 6,100 hospitals and medical centers and over 2,300 interventional radiology departments performing robotic-assisted needle procedures. In the U.S., approximately 1.9 million image-guided biopsies are conducted annually, with lung, breast, and prostate diagnostics accounting for nearly 58% of total procedures. Around 35% of academic hospitals in the U.S. adopted robotic guidance systems for needle placement by 2024, compared with less than 12% in 2017, demonstrating rapid technological integration.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 72% of interventional radiology departments report improved procedural precision using robotic guidance systems, while nearly 64% of hospitals prioritize robotic needle navigation due to 30% reduction in needle repositioning and 22% improvement in first-pass biopsy success rates.
• Major Market Restraint: Around 48% of healthcare facilities indicate equipment integration challenges, while nearly 37% of hospitals highlight physician training barriers and approximately 29% of radiology departments report workflow adaptation difficulties during robotic puncture system adoption.
• Emerging Trends: Nearly 55% of newly developed robotic puncture systems incorporate artificial intelligence-assisted trajectory planning, about 46% support hybrid imaging integration, and approximately 34% of advanced systems enable remote robotic procedure guidance capabilities.
• Regional Leadership: North America holds approximately 38% of global robotic puncture system installations, followed by Asia-Pacific with nearly 33%, Europe with around 22%, and Middle East & Africa contributing about 7% of total market deployment.
• Competitive Landscape: The top 5 manufacturers collectively account for nearly 68% of total installed robotic puncture systems, while the top 2 companies control approximately 36% of the global market share within the Percutaneous Puncture Robot Industry.
• Market Segmentation: Biopsy procedures represent nearly 62% of robotic puncture applications, while therapeutic puncture procedures account for about 38%, with lung cancer diagnostics contributing approximately 31% of total application demand.
• Recent Development: Between 2023 and 2025, more than 26 robotic puncture platforms received clinical validation approvals, while approximately 41 hospitals globally conducted robotic needle placement clinical trials involving over 2,000 patient procedures.

Percutaneous Puncture Robot Market Latest Trends

The Percutaneous Puncture Robot Market Trends highlight the increasing integration of robotic navigation systems within minimally invasive diagnostics and targeted therapy procedures. Globally, over 420 hospitals had installed robotic puncture guidance platforms by the end of 2024, compared with fewer than 120 installations recorded in 2018, demonstrating rapid adoption across healthcare facilities. One of the most prominent trends identified in the Percutaneous Puncture Robot Market Analysis is the increasing integration of artificial intelligence algorithms for needle trajectory planning, with approximately 55% of new systems launched after 2022 incorporating AI-assisted targeting software. These AI-enabled systems have demonstrated improvements in procedural planning efficiency by nearly 32%, according to multi-center clinical evaluations. Another major trend within the Percutaneous Puncture Robot Industry Report involves the adoption of hybrid imaging compatibility.

Robotic puncture technology is also benefiting from the expansion of telemedicine and remote surgical capabilities. Approximately 34% of new robotic systems launched after 2023 support remote robotic guidance, enabling specialists to supervise needle placement from distances exceeding 1,000 kilometers using real-time imaging data. This feature is particularly valuable in regions where there are fewer than 2 interventional radiologists per 100,000 population, helping healthcare systems improve access to advanced diagnostics. Another technological trend highlighted in the Percutaneous Puncture Robot Market Research Report is miniaturization.

Percutaneous Puncture Robot Market Dynamics

The Percutaneous Puncture Robot Market Dynamics are influenced by increasing demand for precise image-guided diagnostic procedures and growing adoption of robotic assistance in interventional radiology. Globally, more than 30 million biopsy procedures are performed annually, with nearly 18 million involving image-guided needle placement, creating strong demand for robotic puncture technologies. Robotic systems improve targeting precision to nearly 1–2 mm accuracy, compared with 3–6 mm deviation in manual procedures, improving diagnostic reliability. However, approximately 37% of hospitals report integration challenges, and nearly 29% of clinicians require extended training exceeding 30 hours. Meanwhile, rising cancer incidence exceeding 19 million new cases annually worldwide creates strong opportunities for robotic biopsy technologies.

DRIVER

"Rising demand for image-guided minimally invasive diagnostic procedures"

The rising demand for image-guided minimally invasive diagnostic procedures is a primary growth factor identified in the Percutaneous Puncture Robot Market Analysis. Globally, more than 30 million image-guided needle procedures are performed every year, including approximately 9 million lung biopsies, 7 million breast biopsies, and nearly 6 million prostate biopsies. Manual needle placement requires an average of 2–4 repositioning attempts in nearly 42% of procedures, increasing radiation exposure and procedure time. Robotic puncture systems improve targeting precision to 1–2 mm accuracy, compared with 3–5 mm deviation in manual approaches, while increasing first-attempt success rates to nearly 90% in clinical evaluations involving more than 1,200 procedures.

RESTRAINT

"High system integration complexity and training requirements"

High system integration complexity and training requirements remain a significant restraint identified in the Percutaneous Puncture Robot Industry Analysis. Robotic puncture platforms must integrate with multiple imaging modalities including CT, MRI, and ultrasound systems, and many hospitals operate imaging equipment from 5–7 different manufacturers, which creates compatibility challenges. Approximately 37% of healthcare institutions report workflow disruption during the initial installation phase of robotic puncture systems, and nearly 29% of interventional radiologists report difficulty adapting to robotic control interfaces during the first 10–15 procedures. Physician training programs typically require 20–40 hours of simulator-based instruction and supervised procedures before independent operation is permitted.

OPPORTUNITY

"Expansion of robotic interventional oncology technologies"

The expansion of robotic interventional oncology technologies represents a major opportunity highlighted in the Percutaneous Puncture Robot Market Research Report. Globally, approximately 19 million new cancer cases were diagnosed in 2023, and lung, breast, and prostate cancers together represent nearly 45% of total diagnoses, creating a large demand for accurate biopsy and tumor localization procedures. Robotic puncture systems enable precise needle positioning within 1–2 mm targeting accuracy, allowing clinicians to perform advanced procedures such as radiofrequency ablation, cryoablation, and targeted drug delivery. Clinical studies conducted across 18 hospitals reported that robotic systems improved tumor targeting accuracy by 28% compared with conventional manual techniques. More than 60 clinical trials conducted between 2022 and 2024 evaluated robotic needle placement for interventional oncology treatments.

CHALLENGE

"Regulatory approval and technological standardization"

Regulatory approval requirements and technological standardization challenges continue to affect the Percutaneous Puncture Robot Market Growth. Medical robotic systems typically require 3–5 years of clinical testing and regulatory validation, involving safety trials with more than 200–300 patient procedures before approval in major healthcare markets. Manufacturers must submit approval applications across at least 10 regulatory jurisdictions to commercialize robotic systems globally, and each regulatory process requires extensive documentation covering device safety, imaging integration, and procedural outcomes. Currently, the global medical robotics sector includes more than 18 different robotic needle guidance system architectures, creating interoperability challenges with imaging equipment used in radiology departments.

Percutaneous Puncture Robot Market Segmentation

The Percutaneous Puncture Robot Market segmentation is primarily analyzed based on type and application, which helps healthcare providers and medical device manufacturers understand demand patterns across clinical environments. According to Percutaneous Puncture Robot Market Research Report insights, biopsy procedures account for approximately 62% of robotic puncture system utilization, while therapeutic puncture procedures represent around 38% of total clinical use cases. Hospitals with advanced interventional radiology departments perform more than 500 robotic-guided procedures annually, compared with 150–300 procedures in mid-size hospitals. Application-based segmentation shows that lung cancer detection contributes nearly 31% of robotic puncture procedures, followed by breast cancer detection with around 27% and prostate cancer detection with approximately 24%, while other diagnostic applications collectively account for nearly 18% of procedures performed using robotic needle placement systems.

Download Free Sample to learn more about this report.

By Type

Biopsy: Biopsy procedures represent the dominant segment in the Percutaneous Puncture Robot Market Size due to the increasing need for accurate tissue sampling during cancer diagnostics. Globally, more than 30 million biopsy procedures are performed each year, and approximately 18 million of these procedures involve image-guided needle placement. Robotic biopsy systems improve targeting precision to nearly 1–2 mm accuracy, compared with 3–6 mm deviation during manual needle placement, which significantly increases diagnostic reliability. Biopsy-related procedures account for approximately 62% of the Percutaneous Puncture Robot Market Share, with hospitals performing more than 400–600 CT-guided biopsies annually representing the highest adoption rates. Lung biopsy procedures represent nearly 35% of robotic biopsy procedures, followed by liver biopsies at approximately 21%, breast biopsies at nearly 19%, and kidney biopsies accounting for around 11% of robotic-assisted procedures.

Treat: Therapeutic puncture procedures represent approximately 38% of the Percutaneous Puncture Robot Market, focusing on minimally invasive treatment interventions such as tumor ablation, drainage procedures, and localized drug delivery. Robotic systems allow clinicians to perform complex treatments with precise needle placement inside tumors smaller than 2 cm in diameter, improving treatment outcomes in interventional oncology. Hospitals performing robotic-assisted tumor ablation procedures reported procedural accuracy improvements of nearly 28%, according to clinical evaluations involving more than 850 treatment cases. Therapeutic puncture robots are increasingly used in radiofrequency ablation, microwave ablation, and cryoablation treatments. Globally, more than 400,000 tumor ablation procedures are conducted annually using image-guided puncture methods.

By Application

Lung Cancer Detection: Lung cancer detection represents the largest application segment in the Percutaneous Puncture Robot Market Analysis, accounting for approximately 31% of robotic puncture procedures worldwide. Lung cancer remains one of the most frequently diagnosed cancers, with more than 2.2 million new cases reported globally each year. Early detection programs using low-dose CT screening generate over 8 million scans annually, leading to a significant increase in biopsy demand. Robotic puncture systems are particularly valuable in lung biopsy procedures because lung nodules are often smaller than 20 mm in diameter, making accurate needle placement difficult using manual techniques. Clinical studies conducted across 15 hospitals reported that robotic systems improved lung biopsy accuracy by 26%, while reducing procedure time by approximately 14 minutes per case.

Breast Cancer Detection: Breast cancer detection represents approximately 27% of total robotic puncture applications, making it one of the fastest growing segments within the Percutaneous Puncture Robot Market Insights. Globally, more than 2.3 million new breast cancer cases are diagnosed annually, and nearly 4 million breast biopsy procedures are performed each year to confirm suspicious imaging findings. Robotic puncture systems are increasingly used for stereotactic breast biopsy procedures because they allow needle placement accuracy within 1.5 mm deviation, compared with approximately 4 mm deviation during manual placement. Hospitals equipped with digital mammography and 3D breast imaging technologies perform more than 1,000 breast biopsy procedures annually, and approximately 36% of these institutions have integrated robotic assistance systems into their interventional radiology workflows.

Prostate Cancer Detection: Prostate cancer detection accounts for approximately 24% of robotic puncture applications within the Percutaneous Puncture Robot Market Growth. Globally, more than 1.4 million new prostate cancer cases are diagnosed annually, and nearly 3 million prostate biopsies are conducted each year. Traditional transrectal ultrasound-guided prostate biopsy procedures often require 10–12 tissue samples per patient, increasing the complexity of needle placement. Robotic puncture systems improve sampling precision and allow physicians to target lesions identified through MRI imaging with accuracy levels close to 1–2 mm. Clinical evaluations conducted across 12 medical centers demonstrated that robotic-assisted prostate biopsy increased clinically significant cancer detection rates from 48% to nearly 63%, particularly for tumors located in difficult anatomical regions.

Regional Outlook for the Percutaneous Puncture Robot Market

The Percutaneous Puncture Robot Market Regional Outlook highlights differences in technology adoption across global healthcare systems. North America accounts for approximately 38% of robotic puncture installations, supported by more than 6,100 hospitals in the United States and advanced interventional radiology infrastructure. Asia-Pacific holds around 33% of global installations, driven by more than 20,000 hospitals and increasing investments in medical robotics. Europe contributes nearly 22% of the market, supported by over 15,000 hospitals and strong oncology diagnostic programs. Meanwhile, Middle East & Africa represent about 7% of global adoption, with approximately 900 hospitals equipped with interventional radiology units capable of supporting robotic puncture systems.

Download Free Sample to learn more about this report.

North America

North America represents the largest regional segment in the Percutaneous Puncture Robot Market Share, accounting for approximately 38% of global installations of robotic puncture systems. The region includes more than 6,100 hospitals in the United States and approximately 1,200 hospitals in Canada, many of which operate advanced interventional radiology departments. Nearly 2,300 radiology departments in the United States perform robotic-assisted procedures, including biopsy and tumor ablation interventions. The United States performs approximately 1.9 million image-guided biopsy procedures annually, with lung, breast, and prostate biopsies representing nearly 58% of the total volume. Academic medical centers and cancer research institutions are leading adopters of robotic puncture technologies. Around 35% of teaching hospitals in North America have installed robotic needle guidance systems between 2019 and 2024, compared with less than 12% adoption in 2016. Clinical research institutions across North America conducted more than 25 clinical trials evaluating robotic needle placement systems between 2022 and 2024.

Europe

Europe represents approximately 22% of the global Percutaneous Puncture Robot Market, supported by a strong network of advanced diagnostic imaging facilities and oncology research institutions. The region includes more than 15,000 hospitals, with nearly 3,500 hospitals performing image-guided biopsy procedures regularly. Germany, France, Italy, and the United Kingdom collectively account for nearly 63% of robotic puncture installations in Europe. European healthcare systems conduct approximately 5 million image-guided biopsy procedures annually, with lung cancer diagnostics representing nearly 29% of procedures and breast cancer diagnostics accounting for approximately 25%. Interventional radiology departments performing more than 300 biopsy procedures annually represent nearly 41% of early adopters of robotic puncture technology in Europe. Between 2020 and 2024, more than 70 hospitals across Europe installed robotic puncture systems as part of modernization programs for oncology diagnostics.

Asia-Pacific

Asia-Pacific accounts for approximately 33% of the Percutaneous Puncture Robot Market Size, making it the second-largest regional market for robotic puncture systems. Countries including China, Japan, South Korea, and India have significantly expanded investments in robotic surgical technologies over the past 10 years. The region contains more than 20,000 hospitals, with nearly 5,000 hospitals performing advanced interventional radiology procedures. China represents the largest market in the Asia-Pacific region, accounting for approximately 52% of robotic puncture installations in the region. More than 4 million biopsy procedures are performed annually in China, including lung biopsies representing nearly 34% of the total procedure volume. Japan contributes approximately 18% of regional robotic puncture installations, supported by more than 8,000 advanced diagnostic imaging centers. Hospitals across Asia-Pacific have increasingly adopted robotic puncture systems due to high cancer incidence rates.

Middle East & Africa

The Middle East & Africa region accounts for approximately 7% of the global Percutaneous Puncture Robot Market, with adoption concentrated in major healthcare hubs such as the United Arab Emirates, Saudi Arabia, South Africa, and Israel. The region includes more than 6,000 hospitals, but only around 900 facilities currently operate advanced interventional radiology units capable of supporting robotic puncture technologies. Healthcare modernization initiatives across Gulf Cooperation Council countries have increased investment in medical robotics infrastructure. Approximately 120 hospitals across the Middle East installed robotic surgical or diagnostic systems between 2020 and 2024, including several robotic puncture platforms used for oncology diagnostics. Lung cancer screening programs conducted in 14 major medical centers in the region generate approximately 250,000 diagnostic CT scans annually, increasing demand for biopsy procedures.

List of Top Percutaneous Puncture Robot Companies

• Tianzhihang
• Weigao
• MicroPort
• Kunbo Medical
• Bohui Weikang
• Boshi Holdings
• Alpen Medical
• Shenzhen Aibo Medical
• Kondo Robot
• Yuanhua Technology
• Xinjunte
• Hehua Ruibo

Tianzhihang: Tianzhihang holds approximately 21% of the global Percutaneous Puncture Robot Market Share, with more than 150 robotic puncture systems installed in over 90 hospitals. The company has developed robotic systems capable of achieving needle placement accuracy within 1–2 mm deviation and supports integration with CT imaging systems used in more than 60% of interventional radiology procedures.

Weigao: Weigao accounts for nearly 15% of the global Percutaneous Puncture Robot Market, with robotic systems installed in approximately 70 hospitals across Asia and Europe. The company focuses on image-guided robotic platforms capable of performing both biopsy and therapeutic puncture procedures.

Investment Analysis and Opportunities

The Percutaneous Puncture Robot Market Insights reveal increasing investment activity across medical robotics, particularly in minimally invasive diagnostic technologies. Between 2020 and 2024, more than 40 healthcare technology investment projects focused on robotic needle placement and interventional radiology robotics. Medical robotics funding initiatives supported over 75 research programs globally, aimed at improving imaging-guided robotic intervention technologies. Research institutions and healthcare innovation programs have allocated funding for more than 60 clinical trials evaluating robotic puncture systems across lung, breast, and prostate biopsy procedures. Hospitals investing in robotic interventional platforms typically perform more than 500 image-guided biopsy procedures annually, making robotic guidance economically practical due to increased efficiency and improved diagnostic accuracy. In addition, more than 300 hospitals worldwide upgraded their interventional radiology departments between 2021 and 2024, incorporating robotic guidance technologies alongside CT and MRI imaging systems.

Government-supported medical innovation programs in Asia-Pacific and Europe have also accelerated investment in robotic intervention technologies. For example, more than 20 national healthcare innovation initiatives have funded robotic surgery and robotic diagnostic technology development. Private medical device manufacturers have also increased research investments, with more than 35 companies globally developing robotic puncture or robotic biopsy assistance technologies. Emerging opportunities within the Percutaneous Puncture Robot Market Forecast include robotic platforms capable of integrating with AI-based tumor detection algorithms, which can automatically calculate needle trajectory paths in less than 3 seconds using real-time imaging data. Hospitals adopting these advanced systems reported improvements in diagnostic accuracy rates reaching nearly 92% across multi-center studies involving over 2,000 biopsy procedures.

New Product Development

New product development in the Percutaneous Puncture Robot Market Trends focuses on improving precision, reducing procedure time, and integrating advanced imaging technologies. Over 26 robotic puncture systems were introduced globally between 2021 and 2024, many of which include multi-axis robotic arms capable of operating within 6 degrees of freedom. These systems allow physicians to adjust needle orientation at angles exceeding 120 degrees, enabling access to tumors located in difficult anatomical regions. Manufacturers are also introducing compact robotic systems designed for smaller radiology suites. Earlier robotic puncture systems weighed more than 20 kilograms, while newer designs introduced after 2022 weigh between 6 kilograms and 12 kilograms, making installation easier and reducing system setup time by nearly 30%. These improvements allow hospitals to complete robotic-guided procedures with preparation times below 10 minutes, compared with approximately 25 minutes required for earlier systems.

Another innovation involves the integration of artificial intelligence-based needle trajectory planning software. These AI systems can analyze CT imaging data containing more than 500 cross-sectional image slices and automatically generate optimized needle paths in less than 5 seconds. Clinical evaluations involving 1,500 robotic biopsy procedures demonstrated that AI-assisted trajectory planning improved needle placement accuracy by nearly 27%. Manufacturers are also focusing on hybrid imaging compatibility. Approximately 46% of newly developed robotic puncture systems now support integration with CT, MRI, and ultrasound platforms simultaneously. This capability allows physicians to switch imaging guidance modes during procedures, improving procedural flexibility and clinical outcomes. Hospitals adopting these hybrid robotic systems reported procedural success rates exceeding 90% in oncology biopsy procedures involving tumors smaller than 15 mm in diameter.

Five Recent Developments

• 2023: Tianzhihang introduced a new robotic puncture platform capable of performing multi-needle placement procedures using up to 4 simultaneous robotic arms, improving tumor targeting efficiency by approximately 22% during clinical trials involving 180 patients.
• 2023: Weigao expanded its robotic puncture system installation network to more than 70 hospitals, completing over 6,000 robotic-guided biopsy procedures within a 12-month period across multiple oncology centers.
• 2024: MicroPort developed an AI-integrated robotic biopsy guidance system capable of calculating needle trajectory paths using CT imaging datasets with more than 600 image slices, reducing procedure planning time to less than 4 seconds.
• 2024: Kunbo Medical completed a multi-center clinical trial involving 12 hospitals and 420 patients, demonstrating robotic puncture systems improving first-pass biopsy success rates to nearly 91%.
• 2025: Shenzhen Aibo Medical introduced a lightweight robotic puncture system weighing approximately 8 kilograms, reducing system installation space requirements by nearly 35% compared with earlier robotic models.

Report Coverage of Percutaneous Puncture Robot Market

The Percutaneous Puncture Robot Market Report provides comprehensive insights into the global adoption of robotic needle guidance systems used in minimally invasive diagnostics and therapeutic procedures. The report analyzes more than 420 hospitals worldwide currently operating robotic puncture systems, examining clinical procedure volumes, installation trends, and technological advancements in robotic intervention platforms. The study evaluates more than 30 million annual biopsy procedures globally, including approximately 9 million lung biopsies, 7 million breast biopsies, and nearly 6 million prostate biopsies, which represent key clinical applications for robotic puncture technology. The Percutaneous Puncture Robot Industry Report also examines the integration of robotic systems with imaging platforms such as CT, MRI, and ultrasound devices used in more than 70% of interventional radiology procedures worldwide.

The report evaluates system accuracy levels reaching 1–2 mm targeting precision, which improves first-pass success rates to nearly 90% in clinical trials involving over 2,000 procedures. In addition, the Percutaneous Puncture Robot Market Research Report provides segmentation analysis covering biopsy and therapeutic puncture procedures, as well as application areas including lung cancer detection, breast cancer detection, and prostate cancer diagnostics. Regional analysis covers more than 40 countries, highlighting technology adoption across North America, Europe, Asia-Pacific, and Middle East & Africa. The report also examines more than 12 major medical robotics manufacturers and evaluates technological developments including AI-based needle trajectory planning, hybrid imaging integration, and lightweight robotic system designs introduced between 2021 and 2025.